Neumora Therapeutics, Inc. 2025 Annual Report Summary

I’ve updated our cheat sheet for Neumora Therapeutics. With the 2025 Annual Report finished, we have a clearer view of their pipeline and the make-or-break moments coming in 2026.

1. What does this company do?

Neumora is a clinical-stage biotech company. As of December 31, 2025, they have no products on the market and earned $0 in revenue. Their business model focuses on "precision neuroscience," using data to identify biological markers that predict which patients will respond to their treatments. Their value depends entirely on moving drugs through FDA clinical trials and eventually finding partners or selling products.

2. The Pipeline: Big Moments to Watch

Neumora is managing several high-stakes projects:

• Navacaprant (Major Depressive Disorder): Following the KOASTAL-1 trial, the company is now running two Phase 3 trials, KOASTAL-2 and KOASTAL-3. We expect results in the second quarter of 2026.
• NMRA-511 (Alzheimer’s Disease Agitation): This drug passed early safety tests. The company is preparing for a Phase 2 study, which is scheduled to start in early 2027.
• NMRA-898 (Schizophrenia): This drug targets the M4 receptor and aims to be a once-daily pill. They expect to report early trial data in the second half of 2026.
• NMRA-215 (Obesity): This program is currently paused to address a safety issue found in animal testing. The company is restarting these safety studies, pushing their first human trials to early 2027.

3. Financial Health: Burning Cash

Neumora is spending heavily to grow. In 2025, they lost about $290 million, with research and development costs accounting for 80% of their spending. By the end of 2025, they held $450 million in cash. With a burn rate of $25–$30 million per month, management expects their current cash to last into the second half of 2027, covering the critical data results expected in 2026.

4. Key Risks

The company’s value is highly sensitive to clinical trial outcomes. The failure of the KOASTAL-1 trial previously caused a sharp drop in value, highlighting the volatility inherent in their drug-focused business model. They face significant execution risk; if trials are delayed or new safety issues arise, the company may need to issue more shares to raise capital, which would dilute existing shareholders. Additionally, they operate in a competitive landscape against much larger pharmaceutical companies.

5. Future Outlook

Neumora is a "story" stock. Their future hinges on the data coming in 2026. Positive results for their depression and schizophrenia programs could increase the company’s value and potentially lead to a partnership or buyout. Conversely, if trials fail, the company will likely face a cash shortage, necessitating further fundraising or the discontinuation of specific programs.

Note: This guide is based on the 2025 Annual Report. Biotech investing is high-risk. Only invest what you are comfortable losing, as these companies are still proving their science works.